Healthcare Stocks

Imugene Limited (ASX:IMU) Progressing with PD1-Vaxx Phase I Trial

 Imugene Limited (ASX:IMU) Progressing with PD1-Vaxx Phase I Trial

Summary Imugene Limited (ASX:IMU) completes the enrolment of three patients under the first cohort under PD1-Vaxx Phase I clinical trial. Following the Phase I trial, a monotherapy optimal biological dose will be determined through a review by ...

Read More...
A Look at Imugene’s robust pipeline of B-Cell Vaccines for Cancer Immunotherapy

A Look at Imugene’s robust pipeline of B-Cell Vaccines for Cancer Immunotherapy

An Australian-headquartered clinical stage immuno-oncology company, Imugene Limited (ASX: IMU) has a robust pipeline of B cell vaccines aimed at treating a variety of cancers. The company?s pipeline includes multiple product candidates that are used ...

Read More...
An Insight into Imugene’s Unique Platform Technology

An Insight into Imugene’s Unique Platform Technology

Imugene Limited (ASX: IMU) is a clinical-stage immuno-oncology company headquartered in Australia that is engaged in developing a range of immunotherapies used to treat and eradicate tumors. The company’s operations are spread across America an...

Read More...
A Glimpse At Biotech Company, Imugene Limited

A Glimpse At Biotech Company, Imugene Limited

A biotechnology company with operations in America and Europe, Imugene Limited (ASX: IMU) deals with the development of cancer immunotherapies targeting B-cell peptide vaccines. The company?s product pipeline comprises of multiple immunotherapy B-cel...

Read More...
Imugene Appoints Leading Biotechnology Executive and Entrepreneur-Dr Jens Eckstein

Imugene Appoints Leading Biotechnology Executive and Entrepreneur-Dr Jens Eckstein

Imugene Limited (ASX: IMU) is a clinical stage immuno-oncology firm. The company is developing a range of new and novel immunotherapies that basically activates the immune system of the patients with cancer and eradicates tumours developed. The comp...

Read More...
Imugene Limited Provided Quarterly Cash Flow Report For March Quarter

Imugene Limited Provided Quarterly Cash Flow Report For March Quarter

Biotechnology company, Imugene Limited (ASX: IMU) is an emerging leader in cancer immuno-oncology which has made significant progress in the recent past. Today, the company has announced its quarterly cash flow report for the quarter ended 31 March 2...

Read More...
Imugene released research study of PD-1 mimotope cancer vaccine

Imugene released research study of PD-1 mimotope cancer vaccine

Imugene Limited (ASX: IMU) is a biotechnology company, having operations in America and Europe is working specifically in the clinical stage of immuno-oncology. Immuno-oncology is an area of research that helps the body to fight cancer through its ow...

Read More...
Imugene Presented New Data On the KEY-Vaxx & B-Vaxx Cancer Vaccine

Imugene Presented New Data On the KEY-Vaxx & B-Vaxx Cancer Vaccine

Imugene Limited (ASX: IMU) is an immuno-oncology company, which is into the clinical stage. The company is engaged in the operations of developing a range of new and novel immunotherapies that has an objective of activating the immune system of cance...

Read More...
Imugene provides Guidance for KEY-Vaxx Cancer Immunotherapy

Imugene provides Guidance for KEY-Vaxx Cancer Immunotherapy

Imugene Limited (ASX: IMU) is an ASX listed biotechnology company based in Sydney, Australia. The company?s primary focus is on the cancer immunotherapy by developing a range of new and novel immunotherapies that can activate the immune system of can...

Read More...
Imugene Reports Dosing Of First Patient In The HER-Vaxx Cancer Vaccine Phase 2 Study: Shares Rose Over 5%

Imugene Reports Dosing Of First Patient In The HER-Vaxx Cancer Vaccine Phase 2 Study: Shares Rose Over 5%

Imugene Limited (ASX: IMU) is into the operations of immuno-oncology. It is in its clinical stage and is into the development of a range of new and novel immunotherapies which helps to activate the immune system of cancer patients to treat and eradic...

Read More...
Imugene released Presentation on KEY-Vaxx and B-Vaxx Cancer Vaccine Programs for the 2019 AACR

Imugene released Presentation on KEY-Vaxx and B-Vaxx Cancer Vaccine Programs for the 2019 AACR

Imugene Limited (ASX: IMU) is a biotechnology company with operations in America and Europe. The company is into the development of biologic therapies for the treatment of cancer while targeting the B-cell peptide vaccines. Among its key vaccines inc...

Read More...
Ad

GET A FREE STOCK REPORT

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK